Recent news on Fazaclo

Avanir 2Q Loss Narrows on FazaClo  -  May 9, 2007
Forbes,Avanir Pharmaceuticals said Wednesday its fiscal 2007 second-quarter loss narrowed on sales of schizophrenia drug FazaClo. The company lost $7.9 million,

AVANIR Pharmaceuticals Invites Investors to Second Quarter ...  -  Apr 23, 2007
PharmaLive.com (press release),Total net revenues for the quarter are expected to be $6.1 million, including FazaClo(R) net revenues of approximately $4.1 million. FazaClo net wholesaler

Market Report -- In Play (AVNR)  -  Apr 23, 2007
MSN MoneyAvanir Pharmaceuticals sees Q2 revs of $6.1 mln - no estimates Co says total net revenues for the quarter are expected to be $6.1 mln, including FazaClo net

Avanir Pharmaceuticals Announces Positive Results of Phase III ...  -  Apr 19, 2007
PipelineReview.com (press release),Avanir currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who

Avanir Pharmaceuticals Provides Business Update and Announces ...  -  Mar 29, 2007
Business Wire (press release),Avanir today also reported it has received expressions of interest in certain Company assets, including several investigational compounds as well as FazaClo

UPDATE 1-Avanir Pharma ends R&D pact with AstraZeneca, Novartis  -  Mar 29, 2007
ReutersIt is also evaluating options including the sale of several investigational compounds and the schizophrenia drug, FazaClo. In the first quarter,

Avanir Pharma Reveals Winding Down Of Two Research Projects; Plans ...  -  Mar 29, 2007
Trading Markets,...for certain assets and the discussions are progressing with multiple parties for the sale of several investigational compounds including FazaClo.

Avanir Announces Restructuring Plan  -  Mar 29, 2007
Houston Chronicle,Avanir said it is in talks with interested parties concerning the sale of some of its investigational compounds and its drug FazaClo, which is approved to

Avanir to restructure as two collaborations wind down  -  Mar 29, 2007
MarketWatch...parties" who have expressed interest in buying certain assets, including several investigational compounds and schizophrenia treatment FazaClo.

Amarin Appoints Paul F. Duffy to New Position of President - US ...  -  Apr 5, 2007
Drug Newswire (press release),At Alamo, he created a fully integrated commercial pharmaceutical company to market Fazaclo, a reformulation of Novartis' anti-psychotic drug, Clozaril.

Avanir may close SD research and development unit  -  Mar 30, 2007
San Diego Union Tribune,One of those compounds is FazaClo, an anti-psychotic drug. The company received an “approvable� letter from the US Food and Drug Administration in January,

Avanir’s Unwinding  -  Mar 31, 2007
Orange County Business Journal,Avanir said it was talking with other companies about possibly selling some of its investigational drug compounds and FazaClo.

AVANIR Pharmaceuticals Appoints New Chief Executive Officer  -  Mar 14, 2007
Business Wire (press release),AVANIR currently markets FazaClo ® , the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who

Avanir Receives FDA Approvable Letter for New Formulation of ...  -  Jan 31, 2007
PharmaLive.com (press release),FazaClo is the only orally disintegrating form of clozapine which is indicated for the management of severely ill schizophrenic patients who fail to respond

AVANIR Pharmaceuticals Provides First Quarter Business Update  -  Feb 9, 2007
Business Wire (press release),The Company is currently evaluating the appropriate method for revenue recognition related to sales of FazaClo ® (clozapine, USP). Until this evaluation is

AVANIR Pharmaceuticals Hires Martin J. Sturgeon as Vice President ...  -  Feb 13, 2007
PharmaLive.com (press release),AVANIR currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who

AVANIR Pharmaceuticals (AVNR) Provides Business Updates and Delays ...  -  Feb 9, 2007
StreetInsider.com (subscription),Announced receipt of an approvable letter from the FDA for a new formulation of its currently marketed antipsychotic drug FazaClo. The Company has responded

Guilty plea in Milberg Weiss case  -  Feb 1, 2007
San Diego Union Tribune,FazaClo is a form of clozapine, which is used for the management of severely ill schizophrenic patients. Information Systems Laboratories of San Diego said

Premarket Movers: Juniper Sinks  -  Jan 31, 2007
Forbes,FazaClo is an orally disintegrating form of clozapine, which is used to manage severely ill schizophrenic patients. The stock rose 31 cents, or 12.8 percent

Market Report -- In Play (AVNR)  -  Jan 31, 2007
MSN MoneyAvanir Pharmaceuticals receives FDA approvable letter for new formulation of currently marketed antipsychotic drug FazaClo Co announces it has received an

Market Report -- In Play (AVNR)  -  Feb 9, 2007
MSN MoneyThe co is currently evaluating the appropriate method for rev recognition related to sales of FazaClo (clozapine, USP). Until this evaluation is complete,

Avanir gets conditional FDA OK for new formulation  -  Jan 30, 2007
ReutersO: Quote, Profile , Research) said on Tuesday that US health regulators approved a new formulation of its already marketed schizophrenia drug FazaClo,

Trader's Beacon: Avanir, Palatin, e-Future, Z-Trim  -  Jan 31, 2007
Ant & Sons...and acceptable labeling from the US Food and Drug Administration (FDA) for a new formulation of its currently marketed antipsychotic drug FazaClo.

Stocks to Watch, Jan. 31: Google, SanDisk and Allstate  -  Jan 30, 2007
FOX News...has received an approvable letter and acceptable labeling from the Food and Drug Administration for a new formulation of its antipsychotic drug FazaClo.

Biotech Day In Review: AstraZeneca Enters Two Partnerships Worth ...  -  Feb 1, 2007
Seeking Alpha,Avanir Pharma (AVNR) received an approvable letter for an orally disintegrating form of FazaClo, or clozapine, for use in severely ill schizophrenic

StreetInsider.com Pre-Open Movers 01/31  -  Jan 31, 2007
StreetInsider.com (subscription),...received an approvable letter and acceptable labeling from the FDA for a new formulation of its currently marketed antipsychotic drug FazaClo.

AVANIR Pharmaceuticals Invites Investors to Its First Quarter ...  -  Jan 16, 2007
PharmaLive.com (press release),AVANIR currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who

AVANIR Selects I-many Contract Lifecycle Management Solution for ...  -  Jan 15, 2007
PharmaLive.com (press release),...the corporate integrity companies require, and we are certain that AVANIR will now be able to achieve their revenue optimization objectives for FazaClo.

AVANIR Pharmaceuticals Reports Fourth Quarter Fiscal 2006 ...  -  Dec 11, 2006
Business Wire (press release),In connection with the acquisition of Alamo Pharmaceuticals in May 2006 the Company began to market FazaClo ® (clozapine, USP). ...

Avanir Pharmaceuticals 4Q loss deepens  -  Dec 11, 2006
BusinessWeekAvanir also said it booked sales of its recently acquired FazaClo schizophrenia drug as "deferred" revenue and will do so until it can estimate future product ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional